Rubin D - Search Results

1

Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease.

Wils P, Jairath V, Sands BE, Magro F, Reinisch W, Rubin D, Danese S, Baumann C, Peyrin-Biroulet L. Wils P, et al. Among authors: rubin d. United European Gastroenterol J. 2023 Oct;11(8):797-806. doi: 10.1002/ueg2.12455. Epub 2023 Sep 5. United European Gastroenterol J. 2023. PMID: 37670487 Free PMC article. Review.

2

When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations.

Siegel CA, Schwartz LM, Woloshin S, Cole EB, Rubin DT, Vay T, Baars J, Sands BE. Siegel CA, et al. Inflamm Bowel Dis. 2010 Oct;16(10):1658-62. doi: 10.1002/ibd.21233. Inflamm Bowel Dis. 2010. PMID: 20186940 Free PMC article.

3

Ethical considerations for clinical trials in inflammatory bowel disease.

Rubin DT, Becker S, Siegler M. Rubin DT, et al. Gastroenterol Hepatol (N Y). 2014 Jan;10(1):37-41. Gastroenterol Hepatol (N Y). 2014. PMID: 24799837 Free PMC article.

4

The Rationale and Growth of Advanced Training in Inflammatory Bowel Disease.

Rubin DT. Rubin DT. Gastroenterology. 2015 Feb 4:S0016-5085(15)00163-8. doi: 10.1053/j.gastro.2015.02.001. Online ahead of print. Gastroenterology. 2015. PMID: 25659281 No abstract available.

5

The rationale and growth of advanced training in inflammatory bowel disease.

Rubin DT. Rubin DT. Gastroenterology. 2015 Apr;148(4):696-700. doi: 10.1053/j.gastro.2015.02.036. Epub 2015 Feb 24. Gastroenterology. 2015. PMID: 25724456 No abstract available.

6

Using a Treat-to-Target Management Strategy to Improve the Doctor-Patient Relationship in Inflammatory Bowel Disease.

Rubin DT, Krugliak Cleveland N. Rubin DT, et al. Am J Gastroenterol. 2015 Sep;110(9):1252-6. doi: 10.1038/ajg.2015.86. Epub 2015 Apr 7. Am J Gastroenterol. 2015. PMID: 25848924 Review.

7

Vedolizumab in the treatment of Crohn's disease.

Tarabar D, Hirsch A, Rubin DT. Tarabar D, et al. Among authors: rubin dt. Expert Rev Gastroenterol Hepatol. 2016;10(3):283-90. doi: 10.1586/17474124.2016.1135051. Epub 2016 Jan 25. Expert Rev Gastroenterol Hepatol. 2016. PMID: 26810276 Review.

8

Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.

Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M. Feagan BG, et al. Clin Gastroenterol Hepatol. 2017 Feb;15(2):229-239.e5. doi: 10.1016/j.cgh.2016.08.044. Epub 2016 Sep 14. Clin Gastroenterol Hepatol. 2017. PMID: 27639327 Free article.

9

Long-term Efficacy of Vedolizumab for Crohn's Disease.

Vermeire S, Loftus EV Jr, Colombel JF, Feagan BG, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. Vermeire S, et al. Among authors: d haens gr, rubin dt. J Crohns Colitis. 2017 Apr 1;11(4):412-424. doi: 10.1093/ecco-jcc/jjw176. J Crohns Colitis. 2017. PMID: 27683798 Clinical Trial.

10

Long-term Efficacy of Vedolizumab for Ulcerative Colitis.

Loftus EV Jr, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. Loftus EV Jr, et al. Among authors: d haens gr, rubin dt. J Crohns Colitis. 2017 Apr 1;11(4):400-411. doi: 10.1093/ecco-jcc/jjw177. J Crohns Colitis. 2017. PMID: 27683800 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,402 results

Search Page

Filters